The story of the "weight-loss drug" has already entered the next phase

Ozempic, Wegovy, Mounjaro, Zepbound. In recent years, the names of GLP-1 drugs have infiltrated not only medical news but also social media, celebrity news, workplace chatter, and diet advertisements. Once discussed as diabetes treatments, these drugs are now widely known as "medications that significantly reduce weight."

However, the current changes are not just a weight-loss trend. The knowledge surrounding GLP-1 drugs is rapidly being rewritten. This is because as a vast number of people worldwide have started using them, effects, side effects, lifestyle inconveniences, and psychological changes that were not visible in clinical trials are emerging from real-world experiences.

As reported by The New York Times, the medical field is now in a "learn-as-you-go" situation. New drugs are typically evaluated under controlled conditions with limited patients and timeframes. However, GLP-1 drugs are being used more broadly, not only by those struggling with obesity and diabetes but also in connection with wider health issues such as cardiovascular diseases, sleep apnea, liver diseases, and kidney diseases.

As a result, the questions have shifted.
From "Does it really help you lose weight?" to
"What else happens besides weight loss?"
From "Does it work in the short term?" to
"Is it a medication for long-term use?"
And from "Is it a drug to compensate for a lack of effort?" to
"How should obesity be treated as a chronic disease?"

From diabetes and obesity drugs to heart, sleep, liver, and kidney

The main reason GLP-1 drugs are gaining attention is not just weight loss. The U.S. FDA has approved Wegovy for reducing the risk of cardiovascular death, heart attack, and stroke in adults with obesity or overweight who have cardiovascular disease. This marked a significant turning point where a "weight-loss drug" is involved in the prevention of cardiovascular events.

Furthermore, Zepbound has been approved as a treatment for moderate to severe obstructive sleep apnea associated with obesity. Sleep apnea is not merely a snoring issue; it is a serious condition where breathing repeatedly stops during sleep, linked to daytime sleepiness, cardiovascular diseases, and metabolic disorders. It is believed that weight loss can alleviate the burden on the airway, leading to symptom improvement.

Changes are also occurring in the liver domain. MASH, or metabolic dysfunction-associated steatohepatitis, is a disease where fat accumulation and inflammation lead to liver fibrosis, which can progress to cirrhosis, liver cancer, or liver failure. Wegovy has been approved as a treatment for MASH with certain fibrosis.

Regarding kidneys, it has been reported that semaglutide has been approved for adults with type 2 diabetes and chronic kidney disease to reduce the risk of worsening kidney disease, kidney failure, and cardiovascular death.

In other words, GLP-1 drugs can no longer be simply described as "weight-loss drugs." They have become a larger medical theme encompassing metabolism, blood vessels, inflammation, organ dysfunction, sleep, appetite, and the brain's reward system.

Is it just "losing weight makes you healthier"?

The important point here is that it is not yet fully delineated how much of the effect of GLP-1 drugs is due to weight loss itself and how much is due to the direct action of the drugs.

When weight is lost, improvements in blood pressure, blood sugar, lipids, sleep apnea, and joint burden are not uncommon. Therefore, it is a natural explanation that positive changes in the heart, liver, and sleep occur as a result of weight loss with GLP-1 drugs.

However, researchers are not only interested in this aspect. GLP-1 receptors may be involved not only in the digestive tract but also in the brain, cardiovascular system, and kidneys, suggesting effects beyond appetite suppression and blood sugar improvement. Areas still being explored include reduced inflammation, improved vascular function, and direct and indirect protective effects on the kidneys and liver.

While this raises expectations, it also necessitates caution. When a single drug appears to work for multiple diseases, there is a tendency to speak of it as a "panacea." However, in medicine, the term "panacea" is often precarious. Behind the effects lie indications, contraindications, side effects, costs, duration, and individual differences.

The evaluation of GLP-1 drugs is now transitioning from "enthusiasm" to "precise differentiation."

On social media, "life-changing" and "scary" run simultaneously

Looking at reactions on social media, the atmosphere surrounding GLP-1 drugs is not simple.

In online communities like Reddit, posts such as "I no longer think about food all day," "the urge to snack has quieted," and "for the first time, I feel like I can control my body" stand out. In English-speaking areas, this constant appetite or thought about food is often referred to as "food noise." Experiences of this "food noise" diminishing due to GLP-1 drugs are described as a significant change beyond just weight for many users.

On the other hand, there are also many concerns such as "nausea is tough," "constipation persists," "I feel fatigued," "I can't enjoy meals," "I feel like my hair is falling out," and "what if it comes back after stopping the drug." Official side effect information lists nausea, diarrhea, vomiting, constipation, abdominal pain, and fatigue. Although voices on social media do not prove medical causality, they provide clues about what patients are struggling with in real life.

In fact, a large-scale analysis of Reddit posts about semaglutide and tirzepatide found that a significant proportion of users who self-reported usage posted about some side effects. Most were gastrointestinal symptoms, but symptoms difficult to capture in traditional clinical trials, such as menstrual changes, chills, and hot flashes, were also discussed. Of course, anonymous posts have limitations regarding age, medical history, concomitant medications, dosage, and diagnostic accuracy. Nonetheless, social media is beginning to play a role as a modern "early warning system for side effects."

Costs and insurance trouble people more than the effects

Another strong reaction on social media is anxiety about costs.

GLP-1 drugs are expensive, and the extent to which they are covered by insurance varies greatly depending on the country, system, insurance company, and applicable diseases. On U.S. Reddit, posts can be found such as "covered for diabetes but not for weight loss," "can't continue out-of-pocket expenses," and "had to stop the drug, and the weight came back."

Here lies a problem separate from the drug's effects. If GLP-1 drugs are considered medications for managing obesity as a chronic disease, they are not something to be used for just a few months but need to be considered as a long-term medical expense. However, the more long-term use is required, the more economic disparity directly translates into treatment disparity.

"People who can't use the drug despite its availability" and "those who can use it for near-cosmetic purposes" exist in the same society. This sense of unfairness also complicates discussions on social media.

The realistic question of what happens if you stop

A concern many have regarding GLP-1 drugs is "will the weight come back if I stop?"

Past studies have shown a tendency for a significant portion of lost weight to return after stopping semaglutide. This does not mean the drug has failed but rather indicates that obesity is a chronic disease. Just as blood pressure may rise after stopping hypertension medication, stopping a drug that affects appetite and weight regulation may cause the body's mechanisms to revert to their original state.

However, this also presents challenges. If the assumption is to continue the drug for life, management including long-term safety, costs, responses during pregnancy or surgery, effects on muscles and bones, and psychological impacts will be necessary. Conversely, if the assumption is to stop in the short term, it will be important to determine how to combine diet, exercise, sleep, and mental care to maintain weight.

On social media, there are voices saying, "This is a treatment, not a temporary diet," while others express, "I'm scared to rely on the drug forever." Both are natural reactions. The issue is not a simple moral argument about whether to rely on the drug but whether a realistic plan can be made that suits the individual's condition, risks, lifestyle, and economic situation.

How to protect muscle will be the next point of contention

A challenge unavoidable with rapid weight loss is the decrease in muscle mass.

When weight is lost, it's not just fat that decreases. To varying degrees, muscle and lean body mass also decrease. GLP-1 drugs are no exception, and experts are cautioning about the decrease in lean body mass, including muscle and bone, as well as nutritional and protein deficiencies.

Recently, research has been advancing on how to support muscle maintenance during weight loss with GLP-1 drugs. Studies on drugs involved in muscle regeneration, protein intake, strength training, and nutritional management by healthcare professionals are gaining attention.

What should not be overlooked here is that "losing weight" and "becoming healthy" are not the same. Even if the numbers on the scale go down, excessive muscle loss can lead to fatigue, increased risk of falls, decreased metabolism, changes in appearance, and a tendency to rebound.

On social media, there are increasing voices saying, "I feel like my strength has decreased along with my weight," "I've started strength training," and "I'm focusing on protein." In future GLP-1 use, it will be important not just to lose weight but to focus on "what to lose and what to protect."

Prejudices of "cheating" and "easy" distance treatment

The perception of people using GLP-1 drugs is also a social issue.

On social media, there are criticisms such as "losing weight with drugs is cheating," "not putting in effort," and "taking shortcuts." On the other hand, from the users' side, there are voices saying, "I didn't change despite years of exercise and dieting," "there are side effects, and it's not easy," and "I can't tell those around me that I'm using the drug."

Obesity has long been treated as a matter of personal responsibility or lack of willpower. However, current medicine considers weight to be influenced by many factors, including genetics, hormones, brain appetite regulation, sleep, stress, medications, social environment, income, and food environment.

The advent of GLP-1 drugs is shaking this old value system. If drugs can significantly change appetite and satiety, the explanation that "people are overweight because they lack willpower" becomes increasingly untenable. Conversely, what this drug is challenging society with is not just obesity itself but also our perception of obesity.

The boundary between cosmetic and medical purposes

Another unavoidable issue is how to consider the use for cosmetic purposes.

GLP-1 drugs can be a significant help for those with medical needs such as obesity or diabetes. However, influenced by social media and celebrity culture, even those without high medical necessity are becoming interested for purposes like "wanting to be a little slimmer" or "losing weight before an event."

This leads to concerns about supply shortages, price increases, counterfeit drugs, and unapproved combination drugs. Use outside of medical supervision, extreme low dosing, and self-judged discontinuation or resumption are also topics on social media.

GLP-1 drugs are not merely cosmetic items. There are points to be checked, such as pancreatitis, gallbladder-related issues, gastrointestinal symptoms, hypoglycemia risk, kidney function, retinopathy, and mental aspects. They are not equally safe or effective for everyone.

Therefore, rather than using them because they are "trendy," it is necessary to confirm with healthcare providers whether they are medically necessary for oneself, what the goals are, what to do if side effects occur, and what the plan is if one decides to stop.

GLP-1 drugs are a hope, but not a magic bullet

The spread of GLP-1 drugs is a significant hope for those suffering from obesity and diabetes. People who have long been told they "aren't trying hard enough" may finally regain control over their appetite and improve their blood sugar, weight, and health indicators. In that sense, these drugs should not be underestimated.

At the same time, overestimation is dangerous. There are side effects. There are cost barriers. There are issues after stopping. Efforts to protect muscle are necessary. Psychological changes and social prejudices cannot be ignored.

What is happening now is not confusion over an unsettled evaluation of the drug, but rather a process where the evaluation is rapidly becoming more precise. Clinical trials, official approvals, doctors' experiences, patients' lives, and voices on social media are overlapping, and the true nature of GLP-1 drugs is gradually becoming visible.

The focus going forward is not just on "whether it helps you lose weight."
Who should use it.
How long it should be continued.
What should be managed alongside it.
How to quickly detect side effects.
How to reduce prejudice against people using the drug.
And how to move away from an era where health is measured solely by weight.

GLP-1 drugs are a major turning point in modern medicine. But their value is not just within the injection pen. The true impact of these drugs on society lies in how we rethink obesity, appetite, health, personal responsibility, and access to healthcare.

Source URL

New York Times article "What We Know About Weight-Loss Drugs Is Rapidly Changing." An article on the latest trends in GLP-1 drugs that served as the starting point for this piece.
https://www.nytimes.com/2026/06/08/well/glp1-drugs-weight-loss.html

U.S. FDA approval for Wegovy's cardiovascular risk reduction indication. Regarding the reduction of cardiovascular death, heart attack, and stroke risk in adults with obesity or overweight who have cardiovascular disease.
https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or

U.S. FDA approval for Zepbound for obstructive sleep apnea. Its positioning as a treatment for moderate to severe OSA with obesity.
https://www.fda.gov/news-events/press-announcements/fda-approves-first-medication-obstructive-sleep-apnea

U.S. FDA approval for Wegovy for MASH treatment. Regarding the indication for metabolic dysfunction-associated steatohepatitis and